Price (delayed)
$0.48
Market cap
$23.44M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.43
Enterprise value
$8.93M
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease
There are no recent dividends present for AIM.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.